脳炎治療市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、治療別、症状別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

脳炎治療の世界市場規模は2024年に186億米ドルとなり、2030年までのCAGRは4.80%で、予測期間中に目覚ましい成長が見込まれています。

脳炎は、脳の炎症を特徴とする病状です。ウイルス感染、自己免疫反応、細菌感染、場合によっては原因不明など、さまざまな要因によって引き起こされます。脳炎は軽症から重症まであり、その症状は根本的な原因や脳の炎症の程度によって大きく異なります。脳炎は、ウイルス（ウイルス性脳炎）、自己免疫反応（自己免疫性脳炎）、細菌（細菌性脳炎）、寄生虫、そして場合によっては原因不明の誘因など、いくつかの要因によって引き起こされます。ウイルスが脳炎の最も一般的な原因です。これは脳炎の最も一般的な形態です。ウイルス性脳炎の原因となるウイルスには、単純ヘルペスウイルス（HSV）、水痘帯状疱疹ウイルス（VZV）、エンテロウイルス、アルボウイルス（例えば、西ナイルウイルス）などがあります。脳炎の症状はさまざまですが、発熱、頭痛、精神状態の変化（錯乱や見当識障害など）、痙攣、筋力低下、言語障害や協調運動障害などがよくみられます。脳炎が重症化すると、昏睡状態に陥ることもあります。例えば、WHOによると、日本脳炎ウイルス（JEV）はデング熱、黄熱病、西ナイルウイルスに関連するフラビウイルスで、主に蚊、特にCulex tritaeniorhynchusによって媒介されます。JEVはアジア諸国におけるウイルス性脳炎の主要な原因であり、年間約10万件の臨床例が報告されています。

市場促進要因

診断の進歩

主な市場課題

新たな病原体

主要市場動向

神経リハビリテーションと支持療法

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の脳炎治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（原発性脳炎、二次性脳炎）
  • 治療別（抗ウイルス剤、ステロイド注射、抗生物質、免疫グロブリン療法、血漿交換療法、その他）
  • 症状別（発熱、眠気、頭痛、人格変化、易刺激性、混乱、脱力感、発作、その他）
  • エンドユーザー別（クリニック、病院、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の脳炎治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の脳炎治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の脳炎治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の脳炎治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの脳炎治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の脳炎治療市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Allergan Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• GlaxoSmithKline plc
• Sun Pharmaceutical Industries Ltd.
• Basilea Pharmaceutica Ltd.
• Abbott Ltd.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Bayer AG

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Encephalitis Treatment Market was valued at USD 18.60 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 4.80% through 2030. Encephalitis is a medical condition characterized by inflammation of the brain. It can be caused by various factors, including viral infections, autoimmune reactions, bacterial infections, and, in some cases, unknown causes. Encephalitis can range from mild to severe, and its symptoms can vary widely depending on the underlying cause and the extent of brain inflammation. Encephalitis can be caused by several factors, including viruses (viral encephalitis), autoimmune reactions (autoimmune encephalitis), bacteria (bacterial encephalitis), parasites, and, in some cases, unknown triggers. Viruses are the most common cause of encephalitis. This is the most common form of encephalitis. Viruses that can cause viral encephalitis include herpes simplex virus (HSV), varicella-zoster virus (VZV), enteroviruses, arboviruses (e.g., West Nile virus), and others. The symptoms of encephalitis can vary but often include fever, headache, altered mental status (such as confusion or disorientation), seizures, muscle weakness, and speech or coordination problems. In severe cases, encephalitis can lead to coma. For instance, according to WHO, the Japanese encephalitis virus (JEV) is a flavivirus related to dengue, yellow fever, and West Nile viruses, primarily transmitted by mosquitoes, especially Culex tritaeniorhynchus. JEV is the leading cause of viral encephalitis in several Asian countries, with approximately 100,000 clinical cases reported annually.

Key Market Drivers

Advancements in Diagnostics

Polymerase chain reaction (PCR) and other molecular techniques have revolutionized the diagnosis of encephalitis, particularly for viral forms. These methods allow for the detection of viral genetic material (DNA or RNA) in cerebrospinal fluid (CSF) or other clinical samples, providing rapid and specific identification of the causative virus. Next-Generation Sequencing (NGS) technologies have enabled comprehensive genomic analysis of pathogens, including viruses, in encephalitis cases. This can help identify rare or emerging pathogens and enhance our understanding of the genetic diversity of viral strains. Serological tests, including enzyme-linked immunosorbent assays (ELISAs), are used to detect specific antibodies in the blood or CSF. These tests can confirm exposure to certain viruses and aid in diagnosis. Advanced neuroimaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, allow for the visualization of brain structures and abnormalities. Neuroimaging can help identify signs of inflammation, lesions, or structural changes associated with encephalitis.

Key Market Challenges

Emerging Pathogens

When a new or emerging pathogen is responsible for encephalitis cases, there may be a lack of specific antiviral or treatment options. Healthcare providers may need to rely on broad-spectrum antivirals until more targeted treatments are developed. Identifying and diagnosing emerging pathogens can be challenging. Existing diagnostic tests may not be effective in detecting these novel pathogens, leading to delays in diagnosis and treatment. Research and development efforts are required to understand the biology of the emerging pathogen and develop effective treatments. This process can be time-consuming and may not provide immediate solutions for patients. Addressing emerging pathogens often requires collaboration among researchers, healthcare organizations, and governments on a global scale. Coordinated efforts are necessary to share data, conduct research, and develop treatments. Healthcare systems and public health agencies need to be prepared to respond to outbreaks of encephalitis caused by emerging pathogens. This includes having strategies for rapid diagnosis, isolation, and treatment of affected individuals. In some cases, emerging pathogens may necessitate the development of vaccines to prevent encephalitis. The process of vaccine development can take time, and there may be challenges in ensuring widespread vaccine coverage. Enhanced surveillance and monitoring systems are crucial for detecting the emergence of new pathogens and tracking their spread. Early detection can lead to faster responses and containment. Emerging pathogens can develop drug resistance over time, making previously effective treatments less effective.

Key Market Trends

Neurorehabilitation and Supportive Care

Healthcare providers are increasingly offering comprehensive care programs that include neurorehabilitation services, along with medical treatment, to address the physical, cognitive, and emotional challenges faced by encephalitis patients. The involvement of rehabilitation specialists, including physical therapists, occupational therapists, and speech-language pathologists, is becoming standard in the care of encephalitis patients. These specialists work to improve mobility, functional independence, and communication skills. Cognitive deficits are common in encephalitis survivors. Cognitive rehabilitation programs focus on improving memory, attention, problem-solving, and other cognitive functions to enhance the patient's overall quality of life. Neurorehabilitation aims to maximize the patient's functional independence, helping them regain lost abilities or develop compensatory strategies to cope with impairments. Treatment plans are increasingly tailored to the specific needs of each patient. Individualized care accounts for the unique challenges and goals of the individual. In some cases, neurorehabilitation can be provided in a home-based setting, making it more accessible and convenient for patients, particularly those with limited mobility. Supportive care services encompass a wide range of offerings, including psychological support, counseling, and assistance with activities of daily living. These services help patients and their families navigate the emotional and practical aspects of living with encephalitis-related disabilities. Recognizing the critical role of caregivers, support services are also extended to caregivers, providing them with the resources, education, and respite they need to care for their loved ones effectively.

Key Market Players

• Allergan Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• GlaxoSmithKline plc
• Basilea Pharmaceutica Ltd.
• Abbott Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Bayer AG
• Sun Pharmaceutical Industries Ltd.,

Report Scope:

In this report, the Global Encephalitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Encephalitis Treatment Market, By Type:

• Primary Encephalitis
• Secondary Encephalitis

Encephalitis Treatment Market, By Treatment:

• Antiviral Agents
• Steroid Injection
• Antibiotics
• Immunoglobulin Therapy
• Plasmapheresis
• Others

Encephalitis Treatment Market, By Symptoms:

• Fever
• Drowsiness
• Headaches
• Personality Changes
• Irritability
• Confusion
• Weakness
• Seizures
• Others

Encephalitis Treatment Market, By End-User:

• Clinic
• Hospital
• Others

Encephalitis Treatment Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Encephalitis Treatment Market.

Available Customizations:

Global Encephalitis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Encephalitis Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Primary Encephalitis, Secondary Encephalitis)
  • 5.2.2. By Treatment (Antiviral Agents, Steroid Injection, Antibiotics, Immunoglobulin Therapy, Plasmapheresis, Others)
  • 5.2.3. By Symptoms (Fever, Drowsiness, Headaches, Personality Changes, Irritability, Confusion, Weakness, Seizures, Others)
  • 5.2.4. By End-User (Clinic, Hospital, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Encephalitis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Symptoms
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Encephalitis Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Symptoms
      • 6.3.1.2.4. By End-User
  • 6.3.2. India Encephalitis Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Symptoms
      • 6.3.2.2.4. By End-User
  • 6.3.3. Australia Encephalitis Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Symptoms
      • 6.3.3.2.4. By End-User
  • 6.3.4. Japan Encephalitis Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Treatment
      • 6.3.4.2.3. By Symptoms
      • 6.3.4.2.4. By End-User
  • 6.3.5. South Korea Encephalitis Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Treatment
      • 6.3.5.2.3. By Symptoms
      • 6.3.5.2.4. By End-User

7. Europe Encephalitis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Symptoms
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Encephalitis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Symptoms
      • 7.3.1.2.4. By End-User
  • 7.3.2. Germany Encephalitis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Symptoms
      • 7.3.2.2.4. By End-User
  • 7.3.3. Spain Encephalitis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Symptoms
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Encephalitis Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Symptoms
      • 7.3.4.2.4. By End-User
  • 7.3.5. United Kingdom Encephalitis Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Symptoms
      • 7.3.5.2.4. By End-User

8. North America Encephalitis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Symptoms
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Encephalitis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Symptoms
      • 8.3.1.2.4. By End-User
  • 8.3.2. Mexico Encephalitis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Symptoms
      • 8.3.2.2.4. By End-User
  • 8.3.3. Canada Encephalitis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Symptoms
      • 8.3.3.2.4. By End-User

9. South America Encephalitis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Symptoms
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Encephalitis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Symptoms
      • 9.3.1.2.4. By End-User
  • 9.3.2. Argentina Encephalitis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Symptoms
      • 9.3.2.2.4. By End-User
  • 9.3.3. Colombia Encephalitis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Symptoms
      • 9.3.3.2.4. By End-User

10. Middle East and Africa Encephalitis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By Symptoms
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Encephalitis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Symptoms
      • 10.3.1.2.4. By End-User
  • 10.3.2. Saudi Arabia Encephalitis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Symptoms
      • 10.3.2.2.4. By End-User
  • 10.3.3. UAE Encephalitis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Symptoms
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Encephalitis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Allergan Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Merck & Co., Inc.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Pfizer Inc.
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. GlaxoSmithKline plc
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Sun Pharmaceutical Industries Ltd.
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Basilea Pharmaceutica Ltd.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Abbott Ltd.
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. F. Hoffmann-La Roche Ltd.
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Novartis AG
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10.Bayer AG
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer